实用临床医药杂志2011，Vol.15Issue(7)：88-90,3.
希罗达在转移性乳腺癌维持治疗中的疗效观察
The observation of capecitabine in the maintenance treatment ofmetastatic breast cancer
赵韬 1邵清 1张汀荣 1赵臻 1殷华芳 1陆向东1
作者信息
- 1. 东南大学附属江阴市人民医院肿瘤三科,江苏,江阴,214400
- 折叠
摘要
Abstract
Objective To explore the efficacy and safety of Capecitabine in the maintenance treatment of metastatic breast cancer (MBC). Methods Sixty-five patients, who have been carried out 6 to 8 cycles of first - line treatment, were divided into experimental group and control group according to the different treatment methods. Within the experimental group ( n = 45), patients were given Capecitabine 800～ 1 000 mg/m2, bid with sustained drug delivery. Within the control group ( n = 20), the effect was observed and Capecitabine maintenance therapy was not giver. The OS, PFS, CR, PR, RR and security in these two groups were observed and compared.Results Compared with the experimental group, the probability of progress, no progress and thecumulative probability of progression- free survival rate were reduced even more apparently in control group. But each time, the cumulative progression-free survival difference was not statistically significant in the two groups (P＞0.05). The OS time was significantly higher in the experimental group, but the difference was not statistically significant (P ＞0.05). In the experimental group,the RR was significantly higher than the control group (P ＜ 0.05). Conclusion In the extension treatment, Capecitabine can significantly prolong survival time and improve clinical effect, but there is a higher incidence of adverse reactions.关键词
乳腺癌/转移性/希罗达/安全性Key words
breast cancer/ metastatic/ capecitabine/ security分类
医药卫生引用本文复制引用
赵韬,邵清,张汀荣,赵臻,殷华芳,陆向东..希罗达在转移性乳腺癌维持治疗中的疗效观察[J].实用临床医药杂志,2011,15(7):88-90,3.
